CD8(+) T-cell reconstitution in recipients of umbilical cord blood transplantation and characteristics associated with leukemic relapse

Blood. 2011 Oct 20;118(16):4480-8. doi: 10.1182/blood-2011-04-349241. Epub 2011 Aug 2.

Abstract

Recipients of umbilical cord blood (UCB) transplantation (UCBT) face a high risk of morbidity and mortality related to opportunistic infections (OI) and leukemic relapse. To understand the molecular basis of these UCBT-related complications, the characteristics of UCB-derived antigen-specific CD8(+) T cells were examined in a group of pediatric UCBT recipients. Compared with the UCB graft inoculum and the late post-UCBT period (12-36 months), declining clonal diversity of UCB-derived CD8(+) T cells specific for the Melan-A(26-35) A27L peptide and high frequencies of PD-1-expressing CD8(+) T cells were observed in the first 3 months after UCBT, a period during which OIs are most frequent. The CD8(+) T-cell compartment predominantly comprised CD45RA(+) CCR7(-) terminally differentiated effector-memory T cells until 6 months after UCBT, at which time the polyfunctionality of antigen-specific CD8(+) T cells was reestablished. Finally, the frequency of PD-1(+) CD8(+) T cells was significantly higher in subjects who subsequently experienced leukemic relapse. This study informs the biologic properties of UCB-derived CD8(+) T cells and provides a rationale for the characteristics of UCBT in terms of immune reconstitution and OI. These results also suggest that the elevated frequency of PD-1(+) CD8(+) T cells could be associated with leukemic relapse in pediatric UCBT recipients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • CD8-Positive T-Lymphocytes / cytology*
  • CD8-Positive T-Lymphocytes / immunology
  • Child
  • Child, Preschool
  • Female
  • Fetal Blood / transplantation*
  • Humans
  • Infant
  • Infant, Newborn
  • Leukemia / prevention & control*
  • Leukemia / surgery*
  • MART-1 Antigen / analysis
  • MART-1 Antigen / immunology
  • Male
  • Phenotype
  • Programmed Cell Death 1 Receptor / analysis
  • Programmed Cell Death 1 Receptor / immunology
  • Recurrence

Substances

  • MART-1 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor